|1.||Pritchard, Rebecca J: 1 article (09/2011)|
|2.||Fricker, Simon P: 1 article (09/2011)|
|3.||Kennovin, Gordon D: 1 article (09/2011)|
|4.||Bisland, Stuart K: 1 article (09/2011)|
|5.||Hirst, David G: 1 article (09/2011)|
|6.||Flitney, Frederick W: 1 article (09/2011)|
09/01/2011 - "L-NAME, AMD6221, and AMD6245 reduced tumor growth by approximately 60% to 75% of control rates. "
09/01/2011 - "Tumor-bearing animals were treated with (i) nitric oxide synthase (NOS) inhibitors, administered via the drinking water, including N(G)-nitro-l-arginine methyl ester (L-NAME), a nonisoform-selective inhibitor, and 2 others that target the inducible (NOS II) enzyme preferentially, namely 1-amino-2-hydroxyguanidine or N-[3-(aminomethyl)benzyl]acetamidine hydrochloride; or (ii) daily injections (intraperitoneally) of 2 Ru(III) polyaminocarboxylates, AMD6221 and AMD6245, both of which are effective NO scavengers. "
|1.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|2.||NG-Nitroarginine Methyl Ester (L-NAME)
|3.||Nitric Oxide Synthase (NO Synthase)